Pardes Biosciences on Tuesday said early human testing of its experimental COVID-19 antiviral pill supports its potential as a standalone treatment and announced plans to go public by merging with a special purpose acquisition company. https://t.co/1xSAEBlh08

— Reuters Health (@Reuters_Health) December 21, 2021